| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(10 years from now) | |
| US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(10 years from now) | |
| US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(10 years from now) | |
| US11827642 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(10 years from now) | |
Ayvakit is owned by Blueprint Medicines.
Ayvakit contains Avapritinib.
Ayvakit has a total of 4 drug patents out of which 0 drug patents have expired.
Ayvakit was authorised for market use on 16 June, 2021.
Ayvakit is available in tablet;oral dosage forms.
Ayvakit can be used as treatment of indolent systemic mastocytosis (ism), treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl).
Drug patent challenges can be filed against Ayvakit from 10 January, 2024.
The generics of Ayvakit are possible to be released after 15 October, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-863) | Jun 16, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 09, 2025 |
| New Indication(I-864) | Jun 16, 2024 |
| Orphan Drug Exclusivity(ODE-356) | Jun 16, 2028 |
| Orphan Drug Exclusivity(ODE-434) | May 22, 2030 |
| Orphan Drug Exclusivity(ODE-366) | Jan 09, 2027 |
| New Indication(I-912) | May 22, 2026 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 10 January, 2024
Market Authorisation Date: 16 June, 2021
Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...
Dosage: TABLET;ORAL
AYVAKIT family patents
